ArticleOncology letters2018
KDM3A is not associated with metastasis and prognosis of breast cancer.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Transcriptomic Profile Analysis of Brain Tissue in the Absence of Functional TRPM8 Calcium Channel.Biomedicines · 2024Article
- Knockout of KDM3A in MDA-MB-231 breast cancer cells inhibits tumor malignancy and promotes apoptosis.Journal of molecular histology · 2024Article
- KDM3A regulates alternative splicing of cell-cycle genes following DNA damage.RNA (New York, N.Y.) · 2021Article
- Extracellular vesicles-encapsulated let-7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis.Journal of cellular and molecular medicine · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lysine demethylase 3A (KDM3A), also known as JMJD1A, has been associated with metastasis and poor prognosis in several cancer types, including renal cell carcinoma, prostate cancer and Ewing sarcoma. However, little is known regarding the clinicopathological significance of KDM3A expression in breast cancer (BCa). To investigate the clinical relevance of KDM3A expression in the setting of BCa, immunohistochemistry was performed on a tissue microarray consisting of 150 commercially available BCa samples. No significant correlation was identified between KDM3A expression and various clinicopathological variables, including clinical stage, pathological grade, tumor size and the expression statuses of human epidermal growth factor receptor 2, estrogen receptor, and progesterone receptor. In addition, no significant association between KDM3A expression and overall prognosis was observed. Taken together, these findings suggest that there is no significant association between KDM3A expression and clinicopathological variables, indicating that KDM3A may not be associated with the malignant behavior of BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.